Effect of Shenqi Huayu Formula combined with transcatheter arterial chemoembolization in the treatment of patients with primary hepatocellular carcinoma
LU Dongyan YE Xiaowei
Department of Oncology, First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangdong Province, Guangzhou 510405, China
Abstract：Objective To evaluate the effect of Shenqi Huayu Formula combined with transcatheter arterial chemoembolization (TACE) in the treatment of patients with primary hepatocellular carcinoma (PHC). Methods Sixty patients with PHC admitted to the First Affiliated Hospital, Guangzhou University of Chinese Medicine from June 2020 to December 2021 were selected and divided into control group and treatment group by random number table method, with 30 cases in each group. Both groups received TACE and postoperative symptomatic treatment, and the treatment group was additionally given Shenqi Huayu Formula. The efficacy of solid tumor in the two groups after four weeks of treatment was evaluated according to the response evaluation criteria in solid tumor 1.1. Traditional Chinese medicine syndrome scores, quality of life- liver cancer scale scores, the levels of serum alpha-fetoprotein (AFP), interleukin (IL)-6, IL-1β, and tumor necrosis factor-α (TNF-α) were compared between the two groups before and four weeks after treatment. Results After four weeks of treatment, there was no significant difference in clinical efficacy between the two groups (P＞0.05). After four weeks of treatment, the scores of hypochondriac pain, abdominal distension, nausea and vomiting, anorexia, spiritlessness and fatigue, and total scores in two groups were lower than those before treatment, and the score of fever was higher than that before treatment, and all syndrome scores and total scores in the treatment group were lower than those in the control group (P＜0.05). After four weeks of treatment, physical function, mental function, symptoms scores, and total scores in both groups were higher than those before treatment, and the treatment group was higher than the control group (P＜0.05). After four weeks of treatment, the levels of serum AFP, IL-6, IL-1β, and TNF-α in two groups were lower than those before treatment, and the treatment group was lower than the control group (P＜0.05). Conclusion Shenqi Huayu Formula combined with TACE can effectively reduce the clinical symptoms of PHC patients, improve their quality of life, and reduce the levels of serum AFP and inflammatory factors.
卢冬彦 叶小卫. 参芪化瘀方联合经导管动脉化疗栓塞治疗原发性肝癌患者的效果[J]. 中国医药导报, 2023, 20(5): 98-101,110.
LU Dongyan YE Xiaowei. Effect of Shenqi Huayu Formula combined with transcatheter arterial chemoembolization in the treatment of patients with primary hepatocellular carcinoma. 中国医药导报, 2023, 20(5): 98-101,110.
京公网安备 11010502046598号